継続的な治療を受けているアラジル症候群(ALGS)の患者におけるOdevixibat(Bylvay)の長期、有効性、および安全性を観察する研究
Alagille症候群(ALGS)の参加者におけるOdevixibatの有効性と安全性を評価する将来のレジストリベースの研究
This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives.
Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching.
The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
調査の概要
状態
条件
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Ipsen Recruitment Enquiries
- 電話番号:See email
- メール:clinical.trials@ipsen.com
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90027
- 募集
- Children's Hospital Los Angeles
-
San Francisco、California、アメリカ、94158
- 募集
- UCSF Benioff Children's Hospital
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64108
- 募集
- The Children's Mercy Hospital
-
St Louis、Missouri、アメリカ、63104
- 募集
- SSM Health Cardinal Glennon Children's Hospital
-
-
New York
-
New York、New York、アメリカ、10016
- 募集
- NYU Langone - NYU Grossman School of Medicine
-
New York、New York、アメリカ、10032
- 募集
- Columbia University Medical Center - Morgan Stanley Children's Hospital of NewYork - Presbyterian (MS-CHONY)
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38105
- 募集
- Le Bonheur Children's Hospital
-
-
Texas
-
Dallas、Texas、アメリカ、75246
- 募集
- Children's Medical Center Of Dallas
-
El Paso、Texas、アメリカ、79902
- 募集
- Proactive El Paso,LLC
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84113
- まだ募集していません
- Primary Children's Hospital (PCH) - Intermountain Healthcare/University of Utah
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients diagnosed with ALGS who start treatment with odevixibat (Bylvay) will be enrolled into the registry. Patients who started odevixibat treatment before the implementation of the registry study may also be enrolled.
説明
Inclusion Criteria:
- Diagnosed with ALGS.
- On (or starting) active odevixibat treatment.
- Signed informed consent and assent, as appropriate. Consent/assent from the participant or legal representative should be obtained, as appropriate, before any study data collection is conducted. Participants who turn 18 years of age (or legal age per country) while participating in the study will be required to provide consent for themselves.
Exclusion Criteria:
- Currently participating in a clinical trial with odevixibat.
- Currently participating in any interventional clinical trial for ALGS.
- Have any contraindication to odevixibat as per the locally approved label.
- Had liver transplant before enrolment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:OTHER
- 時間の展望:PROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Odevixibatで治療され、胆管転換手術または肝臓移植を受けるアラジル症候群(ALG)の参加者の割合。
時間枠:最初の用量から研究の終わりまで(約5年のデータ収集)
|
最初の用量から研究の終わりまで(約5年のデータ収集)
|
|
|
Surgical biliary diversion-free survival
時間枠:From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to the first occurrence of surgical biliary diversion or death. |
From first dose to end of study (approximately 5 years data collection)
|
|
Liver transplant-free survival
時間枠:From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to the first occurrence of liver transplant or death. |
From first dose to end of study (approximately 5 years data collection)
|
|
Overall survival
時間枠:From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to death. |
From first dose to end of study (approximately 5 years data collection)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in Weight
時間枠:From first dose to end of study (approximately 5 years data collection)
|
This endpoint will measure the change in participants' weight from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations. |
From first dose to end of study (approximately 5 years data collection)
|
|
Change from Baseline in Height
時間枠:From first dose to end of study (approximately 5 years data collection)
|
This endpoint will measure the change in participants' height from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations. |
From first dose to end of study (approximately 5 years data collection)
|
|
Percentage of participants with Adverse Events (AEs) associated with fat-soluble vitamin (FSV) deficiencies and their possible sequelae.
時間枠:From signing of the Informed Consent Form (ICF) to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the Informed Consent Form (ICF) to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with suspected hepatotoxic Adverse events (AEs) requiring interruption of odevixibat
時間枠:From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with bleeding AEs
時間枠:From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with AEs
時間枠:From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Ipsen Medical, Director、Ipsen
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CLIN-60240-033
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD 共有時間枠
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
IPD 共有アクセス基準
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。